Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Neurimmune AG has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is currently confined to 1 distinct examiner and 1 distinct art unit. This singular focus suggests that the company's intellectual property is currently centered on a specific pharmaceutical or biotechnological innovation that fits within a single technical classification at the patent office.
The busiest examiner, LEVIN, JOEL D, is assigned 1 busiest examiner pending office action. This action is the only one currently pending for the company, making the examiner's individual perspective the most influential factor in the portfolio's immediate future. The presence of only 1 distinct art unit means that the company does not have to navigate the differing procedural expectations of multiple units.
Practitioners should focus their efforts on the 1 pending office action and the specific examination habits of LEVIN, JOEL D, to ensure a smooth prosecution process. Investigating the examiner's typical approach to Biotechnology & Pharmaceuticals claims can provide a strategic advantage. Resolving the 1 pending office action with this 1 examiner is the primary objective for Neurimmune AG's current patent strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MACFARLANE, STACEY NEE | 1 | 53.5% | +39.6% |
| LEVIN, JOEL D | 1 | 58.1% | +35.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17912166 | MISFOLDED SOD1 ASSAY | MACFARLANE, STACEY NEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17292107 | PATIENT-DERIVED AMYLOID XENOGRAFT NON-HUMAN ANIMAL MODEL | LEVIN, JOEL D | 28d |
| 17912166 | MISFOLDED SOD1 ASSAY | MACFARLANE, STACEY NEE | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17912166 | MISFOLDED SOD1 ASSAY | MACFARLANE, STACEY NEE | 1675 | §102§103§112 | Non-Final OA | — | Pending | Sep 16, 2022 |
| 17292107 | PATIENT-DERIVED AMYLOID XENOGRAFT NON-HUMAN ANIMAL MODEL | LEVIN, JOEL D | 1633 | §103 | Final Rejection | 28d | Pending | May 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial